General Information
DRAVP ID DRAVPe00417
Peptide Name IBP02V5
Sequence SLTQINASVVNIQKEIDRLNEVAKNLNESLIDLQEL
Sequence Length 36
UniProt ID No entry found
Source Synthetic construct(derived from HR2 region of SARS-CoV)
Activity Information
Target Organism SARS-CoV-2,SARS-CoV,MERS-CoV,HCoV-NL63
Assay Cell fusion assay
Activity
Hemolytic Activity No hemolysis information or data found in the reference(s) presented in this entry
Cytotoxicity
Binding Target membrane
Mechanism A six-helical bundle structure is formed by two heptad repeat domains (HR1 and HR2) in S2, juxtaposing the viral and cellular membranes for fusion.The peptide derived from the HR2 sequence can competitively bind to the viral HR1 domain thus exerting antiviral activity.
Structure Information
PDB ID None
Predicted Structure Download DRAVPe00417
Linear/Cyclic Linear
N-terminal Modification Free
C-terminal Modification PEG8-K(Chol)
Other Modification None
Stereochemistry L
Physicochemical Information
Formula C175H299N49O61
Absent amino acids CFGHMPWY
Common amino acids L
Mass 4065.59
Pl 4.36
Basic residues 3
Acidic residues 6
Hydrophobic residues 15
Net charge -3
Boman Index -6835
Hydrophobicity -20.56
Aliphatic Index 138.06
Half Life
Extinction Coefficient cystines 0
Absorbance 280nm 0
Polar residues 9
Literature Information
Literature 1
Title SARS-CoV-2-derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses.
Pubmed ID 34344868
Reference Signal Transduct Target Ther. 2021 Aug 3;6(1):294.
Author Zhu Y, Yu D, Hu Y, Wu T, Chong H, He Y.